Microsoft Word - 151030_Acquisition of Own Shares_16M.docx


Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)


Tokyo, October 30, 2015 - Astellas Pharma Inc. (Tokyo：4503, President and CEO: Yoshihiko Hatanaka, hereinafter called 'the Company') announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is

applicable in accordance with Article 165, paragraph 3 of the Companies Act.


Particulars


  1. Reasons for the acquisition of own shares

    To improve capital efficiency and shareholder return.


  2. Contents of acquisition


    1. Class of shares to be acquired: Common stock of the Company


    2. Total number of shares to be acquired: Up to 16 million shares

      (The percentage compared to the total number of shares outstanding: 0.74 %)


    3. Aggregate amount of acquisition cost: Up to 30 billion yen

    4. Period of acquisition: From November 2, 2015 to December 18, 2015 (Reference)

      5. The status of treasury shares as of September 30, 2015:

      Total number of shares outstanding: 2,157,802,942 shares Number of treasury shares: 64,020,233 shares


      ######


      For inquiries or additional information Astellas Pharma Inc.

      Corporate Communications

      TEL: +81-3-3244-3201, FAX:+81-3-5201-7473

      http://www.astellas.com/en


    distributed by